

# Registry for long-term follow-up of CML patients who discontinued Imatinib after Complete Cytogenetic Response

## 3<sup>rd</sup> Form (Restart of Imatinib)

**(to be filled out at time of 1<sup>st</sup> restart of Imatinib and every 3 months thereafter)**

Demographics/Patient Characteristics		
Center		<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Patient ID		<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Date of birth	ddmmyy	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Gender	0=male 1=female	<input type="checkbox"/>
Disease characteristics		
WHO Performance Scale	%	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Karnofsky-Index	%	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Disease related symptoms	0=no 1=yes	<input type="checkbox"/>
Extramedullary manifestations (apart from liver and spleen)	0=no 1=yes If yes, please specify _____	<input type="checkbox"/>
Spleen size	cm below costal margin, palpated	<input type="checkbox"/> <input type="checkbox"/>
	The longest diameter in ultrasound, cm	<input type="checkbox"/> <input type="checkbox"/>
Hematology		
Hemoglobin	g/dl	<input type="checkbox"/> . <input type="checkbox"/>
Hematokrit	%	<input type="checkbox"/> <input type="checkbox"/>
WBC	x 10 <sup>9</sup> /l	<input type="checkbox"/> <input type="checkbox"/> . <input type="checkbox"/>
Platelets	x 10 <sup>9</sup> /l	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>
Differential (PB) (a minimum of 200 cells should be counted under the microscope)		
Blasts	%	<input type="checkbox"/> <input type="checkbox"/>
Promyelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Myelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Metamyelocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Bands	%	<input type="checkbox"/> <input type="checkbox"/>
Polymorphic nucleated cells	%	<input type="checkbox"/> <input type="checkbox"/>
Basophils	%	<input type="checkbox"/> <input type="checkbox"/>
Eosinophils	%	<input type="checkbox"/> <input type="checkbox"/>
Monocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Lymphocytes	%	<input type="checkbox"/> <input type="checkbox"/>
Normoblasts	(pro 100 leukocytes)	<input type="checkbox"/> <input type="checkbox"/>
Differential (BM)		
BM cellularity (histopathology or smear)	1=low 2=normal 3=high	<input type="checkbox"/>
Blasts in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Promyelocytes in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Basophils in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Eosinophils in BM	% na=no aspiration nd=not done	<input type="checkbox"/> <input type="checkbox"/>
Cytogenetic features		
Ph-chromosome status	1=positive 2=negative 3=unknown	<input type="checkbox"/>

Center |\_\_\_\_\_| Patient ID |\_\_\_\_\_|  
 Date of birth (ddmmmyy) |\_\_\_\_\_|  
 Gender (0=male, 1=female) |\_\_|

Number of evaluated metaphases		_____
Number of Ph-positive metaphases		_____
Karyotype		_____
Other clonal chromosomal anomalies in Ph-positive cells, if yes, please specify % and type	0=no	_____
	1=yes	_____
	%	_____
Other clonal chromosomal anomalies in Ph-negative cells, if yes, please specify % and type	0=no	_____
	1=yes	_____
	%	_____
<b>Molecular biology</b>		
Date of molecular analysis	ddmmyy	_____ _____ _____
Source of material	1=PB 2=BM	_____
Volume	ml	_____
Ratio BCR-ABL/ABL	%	_____ ._____
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	_____ ._____
Nested PCR	1=positive 2=negative 4=not done	_____
Date of molecular analysis	ddmmyy	_____ _____ _____
Source of material	1=PB 2=BM	_____
Volume	ml	_____
Ratio BCR-ABL/ABL	%	_____ ._____
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	_____ ._____
Nested PCR	1=positive 2=negative 4=not done	_____
Date of molecular analysis	ddmmyy	_____ _____ _____
Source of material	1=PB 2=BM	_____
Volume	ml	_____
Ratio BCR-ABL/ABL	%	_____ ._____
Other control gene	Please specify	_____
Ratio BCR-ABL/other gene	%	_____ ._____
Nested PCR	1=positive 2=negative 4=not done	_____
Level of BCR-ABL transcript, i.e. quantitative	1=positive 2=negative 3=unknown	_____
<b>Treatment</b>		
Start of Imatinib treatment	ddmmyy	_____ _____ _____
Dosage per day		_____
End of Imatinib treatment	ddmmyy	_____ _____ _____
	please specify the cause	_____

Center | | | | | Patient ID | | | | |  
 Date of birth (ddmmyy) | | | | | | | | | |  
 Gender (0=male, 1=female) | |

New CML treatment (after discontinuation of Imatinib treatment)	New CML treatment:	0=no 1=yes <input type="checkbox"/>
	If yes, please specify below:	
	Drug:	
	Dosis:	
	Period of administration (ddmmyy):	from                 to
	Drug:	
	Dosis:	
Period of administration:	from                 to	
Drug:		
Dosis:		
Period of administration:	from                 to	
Drug:		
Dosis:		
Period of administration:	from                 to	
Drug:		
Dosis:		
Period of administration:	from                 to	
Restart of Imatinib treatment	ddmmyy	
Dosage per day		
Please specify the cause for restart of Imatinib		
<b>Transplantation</b>		
Transplantation	0=no 1=yes	<input type="checkbox"/>
	If yes, please specify the date (ddmmyy)	
Stage of disease at transplantation	1=first chronic phase 2=second or higher chronic phase 3=accelerated phase 4=blast phase	<input type="checkbox"/>
<b>Survival status</b>		
Blast crisis	0=no 1=yes	<input type="checkbox"/>
	If yes, please specify the date (ddmmyy)	
	type of blast crisis	
Date of death	ddmmyy	
Cause of death	1=CML-related 2=BMT-related 3=treatment associated toxicity 4=not CML-related	<input type="checkbox"/>
	If not CML-related, please specify	